What is ESLA's health score?

Estrella Immunopharma, Inc. (ESLA) has a TradeApes health score of 42 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is ESLA's estimated fair value?

Based on our 5-year discounted cash flow model, Estrella Immunopharma, Inc.'s estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is ESLA undervalued or overvalued?

Our model currently rates ESLA as Inconclusive. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for ESLA... Refresh in a moment for the full analysis.

Estrella Immunopharma, Inc. (ESLA)

Healthcare Inconclusive inconclusive weak

$1.11

Updated: 2026-06-04

TradeApes Score

Financial Strength

35 Weak

Operating Trend

50 Mixed

Relative Value

40 Weak

Capital Allocation

30 Weak

Risk

65 Healthy

Key Findings

+ High ROIC — above 20%, excellent return on invested capital

Unlock Full Report →

− Significant dilution — share count up more than 5% year over year

Unlock Full Report →

1 free score card remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.